
SHORT REPORT

Bacterial infection in exacerbated COPD with changes in sputum characteristics

E. MONSÓ¹*, J. GARCIA-AYMERICH², N. SOLER³, E. FARRERO⁴,
M. A. FELEZ⁵, J. M. ANTÓ⁶ AND A. TORRES³ for the EFRAM Investigators†

¹ Servei de Pneumologia, Hospital Germans Trias i Pujol, Badalona

² Unitat de Recerca Respiratòria i Ambiental, Institut Municipal d'Investigació Mèdica, Barcelona, Spain

³ Servei de Pneumologia, Hospital Clínic i Provincial, Barcelona, Spain

⁴ Servei de Pneumologia, Hospital de Bellvitge, L'Hospitalet del Llobregat, Spain

⁵ Servei de Pneumologia, Hospital del Mar, Barcelona, Spain

⁶ Unitat de Recerca Respiratòria i Ambiental, Institut Municipal d'Investigació Mèdica, Departament de Ciències Experimentals i de la Salut, Universitat Pompeu Fabra, Barcelona, Spain

(Accepted 1 April 2003)

SUMMARY

We examined the risk factors for bacterial exacerbation, defined as the presence of pathogenic bacteria in sputum, in 90 chronic obstructive pulmonary disease (COPD) patients with an exacerbation and changes in sputum characteristics. Smoking, alcohol, lung function, body mass index, medical visits and treatments were the independent variables assessed using multivariable logistic regression modelling (OR, 95% CI). A bacterial exacerbation was diagnosed in 39 (43.3%) of 90 patients. Bacterial exacerbations were more prevalent among current smokers (OR 3.77, 95% CI 1.17–12.12), in patients with poor compliance with inhalation therapy (OR 3.25, 95% CI 1.18–8.93) and with severe lung function impairment (FEV₁ OR 0.96, 95% CI 0.93–1.00). Prior use of antibiotics was a risk factor for *Pseudomonas aeruginosa* infection (OR 6.06, 95% CI 1.29–28.44) and influenza vaccination appeared to have a protective effect against this infection (OR 0.15, 95% CI 0.03–0.67). We conclude that severe impairment of lung function, smoking and poor compliance with therapy are risk factors for bacterial infection in COPD, and *P. aeruginosa* should be suspected in patients who have been treated with antibiotics and in those not vaccinated against influenza.

Using techniques that avoid contamination of the sample by oropharyngeal secretions, such as the protected specimen brush, bacterial infection has been associated with 45–55% of chronic obstructive pulmonary disease (COPD) exacerbations [1–3]. Sputum

culture has the advantage over such invasive procedures of being widely available, and results are considered representative of lower airway secretions when strict cytologic criteria are used for selecting the sample [4, 5]. Up to 80% of COPD patients with changes in their sputum characteristics during an exacerbation, such as increased volume and purulence, can be shown to have a bacterial infection [6]. In these patients, antibiotic therapy improves acute symptoms [7] and decreases the sputum bacterial load [6]. *Haemophilus influenzae*, *Streptococcus pneumoniae* and *Moraxella*

* Author for correspondence: Servei de Pneumologia, Hospital Germans Trias i Pujol, Carretera de Canyet s/n, Apartat de correus 72, 08916 Badalona, Catalonia, Spain.

† EFRAM Investigators: Jordi Alonso, Josep Maria Antó, Esther Barreiro, Glòria Bonet, Joan Escarabill, Eva Farrero, Miguel Angel Felez, Judith Garcia-Aymerich, José Izquierdo, Ramon Marrades, Eduard Monsó, Josep Morera, Maria José Redondo, Néstor Soler, Jordi Sunyer and Antoni Torres.

catarrhalis are the most common microorganisms grown in this clinical context, but *Pseudomonas aeruginosa* is also frequently isolated from patients with severe disease [3, 8]. This organism is generally not susceptible to antibiotics commonly used to treat COPD infections, and so identification of risk factors for *P. aeruginosa* infection is therefore important for the optimization of antibiotic therapy for these patients [9].

The interaction between patient characteristics, such as severity of disease and prior treatment, and bronchial infection in COPD requiring hospital admission has only been sporadically investigated, and recent work has only indicated a higher prevalence of infection when COPD is severe [10]. The aim of this study was to assess a wide range of possible risk factors for bacterial infection in a sample of 90 exacerbated COPD patients reporting an increase in sputum production and/or purulence.

A subset of exacerbated COPD patients who participated in a study of risk factors of COPD exacerbation in the Barcelona area, and reported an increase in volume and/or purulence in sputum on admission (Estudi dels Factors de Risc d'Agudització de la Malaltia pulmonar obstructiva crònica, EFRAM) [11, 12], were included in the present study. COPD exacerbation was the initial admission diagnosis for all enrolled cases in the EFRAM study, defined as an increase in dyspnoea, sputum production or purulence [7]. The diagnosis of COPD was based on medical history, current symptoms, chest X-rays and pulmonary function tests, following the guidelines of the European Respiratory Society [13]. Patients whose chest X-ray suggested bronchiectasis or who had a first diagnosis of pneumonia were not enrolled. A sputum sample was obtained within 48 h of admission to hospital and prior to antibiotic treatment. Patients who had received any type of antibiotic treatment in the week before admission were not included. For patients who had more than one episode of exacerbation in the EFRAM study, only the first episode with a sputum sample available was considered.

All enrolled patients were asked to complete a questionnaire upon admission that included questions on sociodemographic variables, smoking, alcohol consumption, comorbidity, COPD-related medical visits within the last year, current treatments and characteristics of the exacerbation [11, 12]. Outpatient and emergency room visits were not considered as admission to hospital. Rehabilitation was defined as

self-reporting respiratory or other prescribed exercises. Compliance with inhalation therapy was assessed using specific checklists as described elsewhere [11, 14]. At least 3 months after hospitalization and during a stable period, forced spirometry and reversibility testing were performed according to standard techniques [15], using reference values obtained from selected volunteers from the Barcelona area [16].

Sputum samples were considered suitable for culture when <10 epithelial cells and >25 leukocytes per low power magnification field were visualized [5]. In two patients who did not produce sputum and for whom fiberoptic bronchoscopy was indicated (pulmonary nodule, haemoptysis) the sputum sample was obtained using a protected specimen brush (Mill-Rose Laboratories Inc., Mentor, OH, USA) as previously described [2]. Sputum samples were processed by standard microbiological methods [17] and bacteria were considered clinically significant according to the criteria of Cabello et al. [18]. A diagnosis of bacterial related exacerbation was established for all samples growing one or more pathogenic bacteria. For samples obtained using a protected specimen brush, isolates were considered significant when they gave counts of ≥ 1000 c.f.u./ml of one or more pathogenic bacteria.

Data were analysed using the SPSS software package (Chicago, IL, USA). Results were expressed as means with standard deviations and absolute and relative frequencies. To check for possible selection bias, exacerbated COPD patients included in the present study were compared with exacerbated patients in the EFRAM study who reported sputum changes but did not fulfill the inclusion criteria (Student's *t* test or χ^2 test). Bacterial related and non-related COPD exacerbations, defined according to the result of the sputum culture (either spontaneous sputum or brush specimen), were analysed for associations with individual characteristics. Univariate and multivariate analyses were performed using logistic regression modelling, for the following potential risk factors: age, gender, smoking (current or passive), alcohol consumption, comorbidity (expressed as dichotomized variables), FEV₁%, body mass index (expressed as continuous variables), COPD-related admissions (dichotomized as ≤ 2 or > 2) and non-admission visits (dichotomized as ≤ 4 or > 4) within the last year, treatments (influenza vaccination, domiciliary oxygen, rehabilitation, inhaled or oral corticosteroids, antibiotics within the previous 3 months), and compliance with prescribed inhalation therapy. Finally,

Table 1. Descriptive statistics of COPD patients

	Sputum sample		<i>P</i>
	Available	Not-available	
<i>N</i>	90	175	
Sputum sample			
Upon admission, <i>n</i> (%)	68 (77.3)	—	—
The second day after admission, <i>n</i> (%)	20 (22.7)	—	—
Upon admission with PSB*, <i>n</i> (%)	2 (2.2)	—	—
Sociodemographic and clinical characteristics			
Age, <i>m</i> (s.d.)	67.5 (9.9)	69.4 (7.8)	0.12
Gender (male), <i>n</i> (%)	86 (95.6)	164 (93.7)	≥0.20
Current smoking, <i>n</i> (%)	21 (23.3)	47 (26.9)	≥0.20
FEV1 %, <i>m</i> (s.d.)†	31.3 (15.9)	33.3 (14.6)	≥0.20
>2 hospital admissions in last year, <i>n</i> (%)	44 (48.9)	71 (40.6)	≥0.20
>4 non-admission visits in last year‡, <i>n</i> (%)	37 (41.1)	77 (44.0)	≥0.20
Therapy			
Influenza vaccination	63 (70.0)	127 (72.6)	≥0.20
Domiciliary oxygen	33 (36.7)	55 (31.4)	≥0.20
Inhaled corticosteroids	46 (51.1)	115 (65.7)	0.06
Oral corticosteroids§	23 (25.6)	51 (29.1)	≥0.20
Rehabilitation	17 (18.9)	27 (15.4)	≥0.20
Antibiotics in prior 3 months	17 (18.9)	37 (21.1)	≥0.20

* PSB; protected specimen brush.

† Available from 222 subjects.

‡ At emergency room or outpatient clinic.

§ More than 2 weeks last year. Comparison of the two groups using a Student's *t* test or χ^2 test.

the same approach was used to determine specific risk factors for *P. aeruginosa* infection. Results were given as crude and adjusted odds ratios (OR), with 95% confidence intervals (CI). All variables showing an association with the outcome variables ($P < 0.25$) in the univariable analysis were included in the multivariable model, and the most parsimonious model that still explained the data was accepted as final [19]. All statistical tests were two-sided, and a *P*-value ≤ 0.05 was considered as statistically significant.

Ninety of the 265 (34.0%) COPD exacerbation episodes included in the EFRAM study and reporting changes in their sputum characteristics in addition to dyspnoea impairment fulfilled the enrollment criteria for the present study. Patients were mostly men with a high prevalence of current smoking and severe lung function impairment (mean FEV1 31.3%). An increase in sputum production was more often reported (88.9%) than sputum purulence (75.6%). When COPD patients in the present study were compared with non-included patients with the same characteristics in the EFRAM study, no significant differences were found, suggesting that the selected sample was representative of exacerbated COPD patients

Table 2. Bacterial species recovered from COPD sputum samples (*N* = 90)

<i>Haemophilus influenzae</i> , <i>n</i> (%)	12 (13.3)
<i>Streptococcus pneumoniae</i> , <i>n</i> (%)	11 (14.4)
<i>Moraxella catarrhalis</i> , <i>n</i> (%)	3 (3.3)
<i>Pseudomonas aeruginosa</i> , <i>n</i> (%)	12 (13.3)
Enteric Gram negative bacilli, <i>n</i> (%)	1 (1.1)
Any potentially pathogenic bacteria, <i>n</i> (%)	39 (43.3)

requiring admission and reporting sputum changes (Table 1).

Thirty-seven patients produced sputum samples with > 25 leukocytes and < 10 epithelial cells that grew potentially harmful bacteria. Additionally, protected specimen brush samples of two patients grew > 1000 c.f.u./ml of these bacteria. In total, 39 of the 90 (43.3%) patients grew clinically significant bacteria (Table 2).

Positive sputum cultures emerged as significantly associated with current smoking (OR 3.77, 95% CI 1.17–12.12), poor compliance with inhalation therapy (OR 3.25, 95% CI 1.18–8.93) and severe functional impairment (FEV1: OR 0.96, 95% CI 0.93–1.00) (Table 3). Additionally, when *P. aeruginosa* infection

Table 3. Risk factors for bacterial infection in COPD patients requiring admission for exacerbations

	Sputum culture		Crude OR (95% CI)	Adjust. OR (95% CI)	P
	Positive	Negative			
Total	39	51	—	—	—
Age	67.6 (9.8)	67.4 (10.0)	1.00 (0.96–1.04)	—	—
Male	37 (94.9)	49 (96.1)	0.75 (0.10–5.61)	—	—
Current smoking	13 (33.3)	8 (15.7)	2.69 (0.98–7.35)	3.77 (1.17–12.12)	0.03
Passive smoking*	9 (23.1)	12 (23.5)	0.97 (0.36–2.61)	—	—
Alcohol, previous 2 weeks	10 (25.6)	16 (31.4)	0.75 (0.30–1.91)	—	—
Comorbidity	34 (87.2)	46 (90.2)	0.74 (0.20–2.76)	—	—
FEV1 %†	27.6 (11.2)	34.1 (18.3)	0.97 (0.94–1.00)	0.96 (0.93–1.00)	0.05
Body mass index	24.5 (5.3)	24.5 (5.2)	1.00 (0.92–1.08)	—	—
COPD-related visits last year					
>2 hospital admissions	13 (33.3)	22 (43.1)	0.66 (0.28–1.57)	—	—
>4 non-admission visits‡	11 (28.2)	26 (51.0)	0.38 (0.15–0.92)	—	—
Therapy					
Influenza vaccination	24 (61.5)	39 (75.5)	0.49 (0.20–1.23)	—	—
Domiciliary oxygen	17 (43.6)	16 (31.4)	1.69 (0.71–4.02)	—	—
Inhaled corticosteroids	19 (48.7)	27 (52.9)	0.84 (0.37–1.94)	—	—
Oral corticosteroids§	10 (25.6)	13 (25.5)	1.01 (0.39–2.62)	—	—
Rehabilitation	6 (15.4)	11 (21.6)	0.66 (0.22–1.98)	—	—
Antibiotics previous 3 months	10 (25.6)	7 (13.7)	2.17 (0.74–6.34)	—	—
Poor compliance with inhalation	19 (48.7)	16 (31.4)	2.08 (0.88–4.92)	3.25 (1.18–8.93)	0.02

Multivariable logistic regression modelling adjusting for FEV1 % and all covariates showing association ($P \leq 0.25$).

* In current non-smokers.

† Available from 81 subjects.

‡ At emergency room or outpatient clinic.

§ More than 2 weeks last year.

was specifically assessed in the multivariable analysis, positive cultures were significantly linked to lack of influenza vaccination (OR 0.15, 95% CI 0.03–0.67) and antibiotic use within the past 3 months (OR 6.06, 95% CI 1.29–28.44) (Table 4).

In our study sputum cultures demonstrated bacterial infection in more than 40% of the COPD exacerbations with changes in sputum characteristics and infection severe enough to require hospital admission. Increased dyspnoea, sputum production and/or purulence are the criteria currently used to identify COPD exacerbations. Wilson et al. [20] found that 45% of the exacerbated patients reported increased dyspnoea, 77% increased sputum production and 66% purulence. The prevalence of these criteria differs in exacerbated COPD patients requiring admission, most of whom report dyspnoea impairment [8]. Stockley et al. [6] found a higher prevalence of bronchial infection when sputum purulence is reported at the beginning of an episode of exacerbation. This is in agreement with the hypothesis that COPD patients with changes in sputum represent a specific

subpopulation for whom the pathogenesis of the exacerbation is closely related to infection.

We found lung function to be a risk factor for bacterial infection in our patients. Patients with severe COPD had a higher prevalence of positive cultures, mainly growing *H. influenzae*, *S. pneumoniae* and *P. aeruginosa*. This is consistent with the study of Miravittles et al. [10] who found that the sputum cultures from half of the exacerbated COPD patients grew potentially pathogenic bacteria and that bacterial infection was associated with severity of lung function impairment. A similar study found positive sputum cultures in more than 60% of the cases [8], with a higher prevalence of *P. aeruginosa* in those with severe disease (11.5%) than in those with mild COPD (3.3%). Here we found that current smoking (OR 3.77, 95% CI 1.17–12.12) and poor compliance with inhalation therapy (OR 3.25, 95% CI 1.18–8.93), in addition to lung function impairment, were clearly associated with bacterial infection. Current smoking has been related to bronchial colonization by pathogenic bacteria [21, 22], and a strong association

Table 4. Risk factors for *Pseudomonas aeruginosa* in COPD patients requiring admission for exacerbation

	Sputum culture		Crude OR (95% CI)	Adjust. OR (95% CI)	P
	Positive	Negative			
N	12	78			
Age	69.3 (12.4)	67.2 (9.5)	1.02 (0.96–1.09)	—	—
Male	11 (91.7)	75 (96.2)	0.44 (0.04–4.61)	—	—
Current smoking	5 (41.7)	16 (20.5)	2.77 (0.77–9.88)	—	—
Passive smoking*	4 (33.3)	17 (21.8)	1.79 (0.48–6.68)	—	—
Alcohol, previous 2 weeks	5 (41.7)	21 (26.9)	1.94 (0.55–6.78)	—	—
Comorbidity	12 (100.0)	68 (87.2)	—	—	—
FEV1 %†	27.3 (7.4)	32.0 (16.8)	0.98 (0.93–1.02)	0.97 (0.91–1.02)	0.27
Body mass index	24.2 (6.1)	24.6 (5.1)	0.98 (0.87–1.11)	—	—
COPD-related visits last year					
>2 hospital admissions	2 (16.7)	33 (42.3)	0.27 (0.06–1.33)	—	—
>4 non-admiss. visits‡	3 (25.0)	34 (43.6)	0.43 (0.11–1.72)	—	—
Therapy					
Influenza vaccination	5 (41.7)	58 (74.4)	0.25 (0.07–0.86)	0.15 (0.03–0.67)	0.01
Domiciliary oxygen	3 (25.0)	30 (38.5)	0.53 (0.13–2.13)	—	—
Inhaled corticosteroids	5 (41.7)	41 (52.6)	0.64 (0.19–2.21)	—	—
Oral corticosteroids§	5 (41.7)	18 (23.1)	2.38 (0.67–8.42)	2.52 (0.58–10.84)	0.21
Rehabilitation	1 (8.3)	16 (20.5)	0.35 (0.04–2.93)	—	—
Antibiotics pr. 3 months	5 (41.7)	12 (15.4)	3.93 (1.07–14.44)	6.06 (1.29–28.44)	0.02
Poor compliance with inhalation	5 (41.7)	30 (38.5)	1.14 (0.33–3.93)	—	—

Multivariable logistic regression modelling adjusting for FEV1 % and all covariates showing association ($P \leq 0.25$) in the univariate model.

* In current non-smokers.

† Available from 81 subjects.

‡ At emergency room or outpatient clinic.

§ More than 2 weeks last year.

between active smoking and *H. influenzae* infection in exacerbated COPD has been reported [10]. Additionally, our findings suggest that a subset of COPD patients whose compliance with treatment was poor, and for whom monitoring during stable periods might have been inadequate, may be at increased risk for infection.

We found that antibiotic treatment during the previous 3 months was related to *P. aeruginosa* infection (OR 6.06, 95% CI 1.29–28.44) and that the prevalence of this bacterial infection was lower in patients vaccinated against influenza (OR 0.15, 95% CI 0.03–0.67). These associations confirm an earlier study [8], which suggested that previous antibiotic treatment was related to the isolation of *P. aeruginosa* and other Gram negative bacteria. The apparent protective effect of influenza vaccination on *P. aeruginosa* infection has to our knowledge not been previously reported, and is consistent with influenza being a risk factor for pneumonia [23]. The association of some individual characteristics with the presence of *P. aeruginosa* may be significant in distinguishing patients

with this infection and instituting specific anti-pseudomonal treatment.

We conclude that the prevalence of bacterial infection in exacerbated COPD patients requiring admission and reporting changes in their sputum will be higher when current smoking, poor compliance with inhalation therapy and severe lung function impairment are identified. *P. aeruginosa* infection should be suspected in patients who have been treated with antibiotics and in patients who have not been vaccinated against influenza.

ACKNOWLEDGEMENTS

This study was supported in part by grants from Agência de Tecnologia Médica (n 5/34/96) and Sociedad Española de Neumología y Cirugía Torácica. The authors would like to thank M. Machare, M. Maresma, A. Martín, M. J. Rodríguez, S. Alonso, R. Reinón, R. Pedreny, A. Roig, S. Cabrera for the field work, and M. E. Kerans for her help in the preparation of the manuscript.

REFERENCES

1. Fagon JY, Chastre J, Trouillet JL, et al. Characterization of distal microflora during acute exacerbation of chronic bronchitis. Use of the protected specimen brush technique in 54 mechanically ventilated patients. *Am Rev Respir Dis* 1990; **142**: 1004–1008.
2. Monsó E, Ruiz J, Rosell A, et al. Bacterial infection in chronic obstructive pulmonary disease. A study of stable and exacerbated outpatients using the protected specimen brush. *Am J Respir Crit Care Med* 1995; **152**: 1316–1320.
3. Soler N, Torres A, Ewig S, et al. Bronchial microbial patterns in severe exacerbations of chronic obstructive pulmonary disease (COPD) requiring mechanical ventilation. *Am J Respir Crit Care Med* 1998; **157**: 1498–1505.
4. Lode H, Schaberg T, Raffenberg M, Mauch H. Diagnostic problems in lower respiratory tract infections. *J Antimicrob Chemother* 1993; **32** (Suppl A): 29S–37S.
5. Murray PR, Washington II JA. Microscopic and bacteriologic analysis of expectorated sputum. *Mayo Clin Proc* 1975; **50**: 339–344.
6. Stockley RA, O'Brien C, Pye A, Hill SL. Relationship of sputum color to nature and outpatient management of acute exacerbations of COPD. *Chest* 2000; **117**: 1638–1645.
7. Anthonisen NR, Manfreda J, Warren CPW, Hershfield ES, Harding GKM, Nelson NA. Antibiotic therapy in exacerbations of chronic obstructive pulmonary diseases. *Ann Intern Med* 1987; **106**: 1302–1307.
8. Eller J, Ede A, Schaberg T, Niederman MS, Mauch H, Lode H. Infective exacerbations of chronic bronchitis. Relation between bacteriologic etiology and lung function. *Chest* 1998; **113**: 1542–1548.
9. Alvarez F, Bouza E, Garcia-Rodriguez JA, et al. Antimicrobial therapy in exacerbated chronic obstructive pulmonary disease. *Arch Bronconeumol* 2002; **38**: 81–89.
10. Miravittles M, Espinosa C, Fernandez-Laso E, et al. Relationship between bacterial flora in sputum and functional impairment in patients with acute exacerbations of COPD. *Chest* 1999; **116**: 40–46.
11. Garcia-Aymerich J, Barreiro E, Farrero E, et al. Patients hospitalized for chronic obstructive pulmonary disease (COPD) have a high prevalence of modifiable risk factors of exacerbation – EFRAM study. *Eur Respir J* 2000; **16**: 1037–1042.
12. Garcia-Aymerich J, Monsó E, Marrades RM, et al. Risk factors for hospitalization for a chronic obstructive pulmonary disease exacerbation – EFRAM Study. *Am J Respir Crit Care Med* 2001; **164**: 1002–1007.
13. Siafakas NM, Vermeire P, Pride NB, et al. Optimal assessment and management of chronic obstructive pulmonary disease (COPD). *Eur Respir J* 1995; **8**: 1398–1420.
14. Van der Palen J, Klein JJ, Kerkhoff AHM, Van Herwaarden CL. Evaluation of the effectiveness of four different inhalers in patients with chronic obstructive pulmonary disease. *Thorax* 1995; **50**: 1183–1187.
15. American Thoracic Society. Standardization of spirometry: 1987 update. *Am Rev Respir Dis* 1987; **136**: 1285–1298.
16. Roca J, Sanchis J, Agustí-Vidal A, et al. Spirometric reference values from a Mediterranean population. *Bull Eur Physiopathol Respir* 1986; **22**: 217–224.
17. Balows A, Hausler WJ, Herrmann KL, Isenberg HD, Shadomy HJ. *Manual of clinical microbiology*, 5th edn. Washington DC, American Society of Microbiology, 1991.
18. Cabello H, Torres A, Celis R, et al. Bacterial colonization of distal airways in healthy subjects and chronic lung disease: a bronchoscopic study. *Eur Respir J* 1997; **10**: 1137–1144.
19. Hosmer DW, Lemeshow S. *Applied logistic regression*. New York: John Wiley and Sons, 1989.
20. Wilson R. Outcome predictors in bronchitis. *Chest* 1995; **108**: 53S–57S.
21. Monsó E, Rosell A, Bonet G, et al. Risk factors for lower airway bacterial colonization in chronic bronchitis. *Eur Respir J* 1999; **13**: 338–342.
22. Zalacaín R, Sobradillo V, Amilibia J, et al. Predisposing factors to bacterial colonization in chronic obstructive pulmonary disease. *Eur Respir J* 1999; **13**: 343–348.
23. Nichol L, Baken L, Nelson A. Relation between influenza vaccination and outpatient visits, hospitalization, and mortality in elderly persons with chronic lung disease. *Ann Intern Med* 1999; **130**: 397–403.